Regulatory press release

Nanologica Receives Order of NLAB Saga® Worth appx SEK 8.5 Million from Recurring Customer in China

Nanologica has received yet another order for the company's silica-based purification media NLAB Saga® from the Chinese pharmaceutical manufacturer Chengdu Shengnuo Biopharm Co. ("Shengnuo"). The order is worth approximately SEK 8.5 million and the customer uses Nanologica's purification media in the production of a GLP-1 analogue.

Since June 2024, Shengnuo has placed five orders of NLAB Saga® with a total value of approximately SEK 18 million.

”The Chinese market is very interesting for us and we put a lot of focus on this customer and similar customers there. Our assessment is that the market for silica for preparative chromatography is growing rapidly in China, even faster than earlier assessments we have made. We are starting to take steps into the Chinese market, although it will probably take a while longer before we can take significant market shares. However, the fact that Shengnuo continues to order NLAB Saga® once again confirms that our product is of high quality and competitive”, CEO Andreas Bhagwani comments.

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

About Chengdu Shengnuo Biopharm Co., Ltd.
Chengdu Shengnuo Biopharm is one of the leading peptide manufacturers on the Chinese market with a large number of key technologies for large-scale production of peptide drugs. The company was founded in Chengdu, China in 2001 and in 2013 the subsidiary Shengnuo Peptide USA, Inc. was established, which offers contract manufacturing of peptides for the global pharmaceutical market. For further information, please visit www.snbiopharm.com.